Glaxosmithkline Pharmaceuticals' Q1 FY 2026-27 Quarterly Results
- 04 Aug 2026
Result Summary
- Glaxosmithkline Pharmaceuticals Ltd reported a 4.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 15.7%.
- Its expenses for the quarter were up by 0.2% QoQ and 15.8% YoY.
- The net profit decreased 14.6% QoQ and increased 15.7% YoY.
- The earnings per share (EPS) of Glaxosmithkline Pharmaceuticals Ltd stood at 14 during Q1 FY 2026-27.
Financial Statments for Q1 FY 2026-27
(₹ crores) | Q1FY27 | Q4FY26 | Q1FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 982.20 | 1031.25 | 848.89 | -4.8% | 15.7% |
Total Expenses | 659.75 | 658.15 | 569.91 | 0.2% | 15.8% |
Profit Before Tax | 322.45 | 373.10 | 278.98 | -13.6% | 15.6% |
Tax | 85.27 | 95.24 | 73.97 | -10.5% | 15.3% |
Profit After Tax | 237.18 | 277.86 | 205.01 | -14.6% | 15.7% |
Earnings Per Share | 14.00 | 16.40 | 12.10 | -14.6% | 15.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
GlaxoSmithKline Pharmaceuticals Ltd is a prominent entity in the pharmaceutical industry, known primarily for its diverse range of pharmaceutical products. The company manufactures and markets medicines and vaccines for various therapeutic areas, including respiratory, oncology, and immunology. As of the latest reports, GlaxoSmithKline Pharmaceuticals Ltd continues to maintain a significant presence in the Indian pharmaceutical market. However, specific recent major developments regarding its operational strategies or market expansions are not included in the provided data.
Revenue
In the first quarter of the fiscal year 2027, GlaxoSmithKline Pharmaceuticals Ltd reported a total income of ₹982.20 crores. This represents a year-over-year growth of 15.7% compared to Q1FY26, where the total income was ₹848.89 crores. However, there was a quarter-over-quarter decline of 4.8% from Q4FY26, which recorded a total income of ₹1031.25 crores. This data reflects a notable growth in revenue over the year, despite the decrease from the previous quarter.
Profitability
The company's profit before tax for Q1FY27 was ₹322.45 crores, indicating a year-over-year increase of 15.6% from ₹278.98 crores in Q1FY26. Nevertheless, the profit before tax saw a decrease of 13.6% quarter-over-quarter from Q4FY26's ₹373.10 crores. The profit after tax for the same quarter was ₹237.18 crores, also marking a year-over-year increase of 15.7% from ₹205.01 crores in Q1FY26, but a quarter-over-quarter decline of 14.6% from ₹277.86 crores in Q4FY26. Earnings per Share (EPS) followed a similar pattern, standing at ₹14.00 in Q1FY27, compared to ₹12.10 in Q1FY26, and ₹16.40 in Q4FY26.
Operating Metrics
The total expenses for GlaxoSmithKline Pharmaceuticals Ltd in Q1FY27 amounted to ₹659.75 crores, showing a year-over-year increase of 15.8% from ₹569.91 crores in Q1FY26. On a quarter-over-quarter basis, expenses saw a minimal increase of 0.2% from ₹658.15 crores in Q4FY26. The tax component for Q1FY27 was ₹85.27 crores, up by 15.3% year-over-year from ₹73.97 crores in Q1FY26, but down by 10.5% quarter-over-quarter from ₹95.24 crores in Q4FY26. These figures illustrate the company's operational cost dynamics over the periods in question.
FAQs
Glaxosmithkline Pharmaceuticals Ltd announced its Q1 FY 2026-27 results on 4 August, 2026.
Glaxosmithkline Pharmaceuticals Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Glaxosmithkline Pharmaceuticals Ltd Q1 FY 2026-27 results include:
- Revenue: ₹982.20 crore
- Net Profit: ₹237.18 crore
- EBITDA: ₹339.26 crore
- Year-over-Year Growth: 15.7%
- Quarter-over-Quarter Growth: -4.8%
Glaxosmithkline Pharmaceuticals Ltd reported a net loss of ₹237.18 crore in Q1 FY 2026-27, reflecting a 15.7% year-over-year growth.
Glaxosmithkline Pharmaceuticals Ltd posted a revenue of ₹982.20 crore in Q1 FY 2026-27.